Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer

NCT06014255 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

219

Enrollment

OTHER

Sponsor class

Conditions

Prostate Cancer

Interventions

DRUG: Enoblituzumab
OTHER: Standard of Care

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Collaborators

[object Object]